MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Psoriasis: Treatment and Pathogenesis
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,393 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,393 works in the cohort · of 4,299,418page 39 of 48

Labels cover 8 of 2,393 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,393 of 2,393 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Efficacité de bimékizumab sur 2 ans sur l’atteinte unguéale et le cuir chevelu chez les patients atteints de psoriasis en plaques modéré à sévère qui sont passés d’adalimumab, d’ustékinumab ou de sécukinumab au bimékizumab : résultats des phases 3/3b
A. Bouznad, R.B. Warren, B. Strober, A. Pinter, A. Blauvelt, M. Sebastian +4 more
2022· article· fr· Annales de Dermatologie et de Vénéréologie - FMC· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
venueno affno abstractunlabeled
10.1016/s1541-9800(12)70379-4
2000· article· en· Time to knit· Immunology and Microbiology
machine prediction:candidate · insufficient_payloadconsensus · insufficient_payload
0
citations
venueno affno abstractunlabeled
Fatal COVID19 in pd patient on IL-23 Inhibitor
Alexander Borrero-Arvelo, C. Crear, Aksha Shetty
2021· article· en· Hemodialysis International· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
venueno affno abstractunlabeled
10.1016/s1541-9800(08)70430-7
2000· article· en· Time to knit· Immunology and Microbiology
machine prediction:candidate · insufficient_payloadconsensus · insufficient_payload
0
citations
affno abstractunlabeled
Maintien de la réponse chez des patients souffrant de psoriasis en plaques chronique traités par certolizumab pégol pendant 48 semaines : résultats poolés des études de phase III CIMPASI-1, CIMPASI-2 et CIMPACT
Matthias Augustin, Jolanta Węgłowska, Mark Lebwohl, C. Paul, Vincent Piguet, Howard Sofen +9 more
2018· article· fr· Annales de Dermatologie et de Vénéréologie· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Le bimékizumab améliore la qualité de vie chez les patients atteints de rhumatisme psoriasique actif, naïfs de biologiques ou avec réponse inadéquate aux anti-TNF : résultats à 16 semaines de 2 études de phase III randomisées, contrôlées par placebo
Laure Gossec, Dafna D. Gladman, Lars Erik Kristensen, Diamant Thaçi, Paolo Gisondi, M. Elaine Husni +8 more
2022· article· fr· Revue du Rhumatisme· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
aboutno affunlabeled
Arachnoscelis Karny 1911
2013· article· en· Zenodo (CERN European Organization for Nuclear Research)· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
aboutno affunlabeled
Grotea perplexa Slobodchikoff 1970
2019· article· en· Zenodo (CERN European Organization for Nuclear Research)· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
venueno affunlabeled
Psoriasis rupioïde touchant les mains
Pedro Jesús Gómez‐Arias, Antonio José Vélez García‐Nieto
2021· article· fr· Canadian Medical Association Journal· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
aboutno affunlabeled
Heredity of psoriasis
D Belić, Sonja Ristic-Nikolic, Saveta Damjan, Iljana Ratkov, Matilda Ceke
2004· article· en· Medicinski pregled· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Abstracts of Invited Speakers
Bernhard Banaschewski, William DeMeo, François G. Dorais, Heinz-Peter Gumm
2007· article· en· Journal of the European Academy of Dermatology and Venereology· Immunology and Microbiology
machine prediction:candidate · insufficient_payloadconsensus · insufficient_payload
0
citations
affno abstractunlabeled
Effect van behandeling met UVB op psoriasis
Gamze Pişkin, M. R. Sylva-Steenland, J. D. Bos, Marcel B. M. Teunissen
2004· article· nl· Data Archiving and Networked Services (DANS)· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations

How this was built: Screen · Findings · About